TABLE 1.
Characteristicsa | No. (%) of patients (n = 24) |
---|---|
Male sex | 13 (54) |
Age (median years [IQR]) | 57.5 [49.4–61.2] |
Pretransplant diagnosis | |
IPF | 13 (54) |
COPD | 10 (42) |
Hemangiomatosis | 1 (4) |
Transplant type | |
Bilateral | 19 (79) |
Single | 5 (21) |
Immunosuppressive drugs | |
TAC+MMF+MPD | 19 (79) |
TAC+MPA+MPD | 2 (8) |
TAC+RAP+MPD | 2 (8) |
TAC+MPD | 1 (4) |
Days from transplantation to positive culture (median [IQR]) | 64 [26–820] |
Hospital admission | 11 (46) |
ICU admission >48 h | 5 (21) |
Antibiotics in the 3 previous mo | 20 (83) |
BOS | 3 (13) |
MPD intravenous pulses in the 3 previous mo | 2 (8) |
Culture type | |
BALF or BA | 19 (79) |
Sputum | 4 (17) |
Tracheal aspirate | 1 (4) |
No. of positive cultures at diagnosis | |
1 | 10 (42) |
2 | 7 (29) |
3 | 5 (21) |
4 | 2 (8) |
Culture | |
Monomicrobial | 18 (79) |
Polymicrobial | 6 (25) |
Bronchoscopy performed | 19 (79) |
Mucosal plaque | 10 (53) |
Purulent secretions | 9 (47) |
BA, bronchial aspirate; BALF, bronchoalveolar lavage fluid; BOS, bronchiolitis obliterans syndrome; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IPF, idiopathic pulmonary fibrosis; IQR, interquartile range; MMF, mycophenolate mofetil; MPA, mycophenolic acid; MPD, methylprednisolone; RAP, rapamycin; TAC, tacrolimus.